

# Association of p65 and C/EBP $\beta$ With HIV-1 LTR Modulates Transcription of the Viral Promoter

Ruma Mukerjee,<sup>1</sup> Bassel E. Sawaya,<sup>1</sup> Kamel Khalili,<sup>1</sup> and Shohreh Amini<sup>1,2\*</sup>

<sup>1</sup>Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, Pennsylvania 19122

<sup>2</sup>Department of Biology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122

**Abstract** In human immunodeficiency virus type 1 (HIV-1) latently infected cells, NF- $\kappa$ B (NF- $\kappa$ B) plays a critical role in the transcriptional induction of the HIV-1 promoter. The *trans*-activating ability of NF- $\kappa$ B can be modified by another nuclear factor C/EBP $\beta$  that can physically bind to NF- $\kappa$ B and regulate its activity. Because the HIV-1 promoter also contains a C/EBP $\beta$  site adjacent to the NF- $\kappa$ B site, the present study examined cooperative functional *in vivo* interaction of the p65 subunit of NF- $\kappa$ B and C/EBP $\beta$ , and the impact of Tat in this event. We demonstrated that ectopic expression of p65 along with Tat increases p65 binding to HIV-1 LTR, and that this increase correlates with enhanced HIV-1 promoter activity. Further, co-expression of C/EBP $\beta$  and Tat leads to a decrease in p65 binding, which allows C/EBP $\beta$  to bind more efficiently to the LTR. Inhibition of p65 expression by siRNA significantly decreases C/EBP $\beta$ -binding and LTR expression. Using ChIP assay, we confirmed the existence of an interchange between p65 and C/EBP $\beta$  and their abilities to bind to the LTR *in vivo*. These observations demonstrate that a delicate balance of interaction between p65, C/EBP $\beta$ , and Tat can dictate the level of HIV-1 LTR transcription. *J. Cell. Biochem.* 100: 1210–1216, 2007. © 2006 Wiley-Liss, Inc.

**Key words:** NF- $\kappa$ B; transcription; HIV-1; C/EBP $\beta$

The human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) serves as a common point for regulation by many cellular and viral proteins such as NF- $\kappa$ B, Sp1, C/EBP $\beta$  [Pereira et al., 2000; Coyle-Rink et al., 2002]. NF- $\kappa$ B is an inducible cellular transcription factor that regulates expression of a wide variety of cellular and viral genes, including that of HIV [Nabel and Baltimore, 1987; West et al., 2001; Muthumani et al., 2003]. In cells, NF- $\kappa$ B, a hetero- or homodimer consisting of the Rel family proteins p65 (RelA), RelB, c-Rel, p50/p105, and p52/p100, resides in the cytoplasm

and is complexed with an inhibitory molecule, I $\kappa$ B [Phelps et al., 2000; Ghosh and Karin, 2002]. Phosphorylation targets I $\kappa$ B $\alpha$  for its ubiquitination and degradation by the  $\beta$ -transducin repeat-containing protein ubiquitin ligase and 26S proteasome, respectively, thus allowing free NF- $\kappa$ B to translocate to the nucleus to activate gene expression [Karin and Ben-Neriah, 2000; Trubiani et al., 2000]. The role of NF- $\kappa$ B in activating HIV transcription has been extensively studied. HIV-1 replication is positively regulated by several cytokines, or T-cell activators, most of which act either completely or partially via NF- $\kappa$ B. NF- $\kappa$ B has been shown to regulate viral transcription via the two NF- $\kappa$ B sites located in the HIV-1 LTR enhancer region [West et al., 2001]. This effect has been shown to be further enhanced through synergism with Sp1 [Chun et al., 1998; Mischitelli et al., 2005]. In HIV-1 latently infected cells, activation of NF- $\kappa$ B could trigger the transcription of viral genes, including the transactivator Tat, resulting in an explosive increase in HIV replication [Demarchi et al., 1996]. Treatment with compounds that block

Grant sponsor: NIH; Grant numbers: P01 NS30916, P01 NS43980.

\*Correspondence to: Shohreh Amini, PhD, Departments of Neuroscience and Biology, Center for Neurovirology, Temple University School of Medicine, 1900 N. 12th Street Philadelphia, Pennsylvania 19122.

E-mail: shohreh.amini@temple.edu

Received 20 July 2006; Accepted 9 August 2006

DOI 10.1002/jcb.21109

© 2006 Wiley-Liss, Inc.

NF- $\kappa$ B activation results in inhibition of HIV-1 gene expression and viral replication [Pande and Ramos, 2003].

The CAAT/enhancer binding protein (C/EBPs) family of transcription factors contains six members ( $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$ ,  $\epsilon$ , and  $\zeta$ ) and is characterized by the presence of a COOH-terminal basic DNA binding domain and a leucine zipper domain that promotes homo- and heterodimerization of the different family members [Cassel and Nord, 2003; Barber et al., 2004]. These latter factors, which are induced by several cytokines, play key roles in numerous cellular responses, including immune and inflammatory processes, by regulating cytokine and acute phase response genes [Cassel and Nord, 2003]. Among their many functions, the C/EBP family of proteins is also involved in the regulation of cellular and viral gene expression (e.g., HIV-1 LTR) [Schwartz et al., 2000]. In this regard, C/EBP $\beta$  was shown to interact with HIV-1 LTR DNA through two binding sites known as C/EBP sites I and II [Tesmer et al., 1993].

Thus, the presence of putative binding sites for both NF- $\kappa$ B and C/EBP $\beta$  in the 5'-flanking region of the *HIV-1* gene prompted us to assess their role in the regulation of viral transcription, as well as their mutual effect on each other's binding capabilities in vivo.

## MATERIALS AND METHODS

### Plasmids

HIV-1 LTR-CAT reporter plasmid, CMV-Tat (86 aa), CMV-p65, and CMV-C/EBP $\beta$  plasmids were described previously [Amini et al., 2002; Abraham et al., 2005].

### Cell Culture, Transfection, and CAT Assays

The HL3T1 HeLa-derived cell line contains stably integrated, silent copies of the HIV-1 LTR promoter linked to the *CAT* gene. Cells were transfected with expression vector using the lipofectamine transfection reagent according to the manufacturer's protocol (Roche, Indianapolis, IN). To control the concentration of the promoter DNA sequence in transfection, pcDNA<sub>3</sub> empty plasmid was added to the transfection mixture. Each transfection was repeated a minimum of three separate times with at least three different plasmid preparations. Cell extracts were prepared 48 h after transfection, and CAT assays were performed

as previously described [Sawaya et al., 1998; Coyle-Rink et al., 2002].

### RNA Interference

Transient knockdown of p65 was performed with p65-specific siRNA: 5'-GCCCUAUCC-CUUUACGUCAdTdT (Dharmacon Research, Inc., Lafayette, CO). After 24 h of plating, cells were rinsed once with Optimem. siRNA was added at a final concentration of 50 nM by the method of Surabhi and Gaynor [2002]. Western blot analysis of protein extracts from untransfected cells or cells transfected with p65-specific siRNA using anti-p65 was performed. For loading controls, anti-Grb2 antibody was used. Control non-targeting siRNA was also obtained from Dharmacon.

### Chromatin Immunoprecipitation (ChIP) Assay

HL3T1 cells were grown overnight in 100-mm dishes to 60%–70% confluency. Cells were then transfected with 1  $\mu$ g of CMV-Tat, CMV-p65, and/or CMV-C/EBP $\beta$  expression plasmids using various combinations, using a lipofectamine transfection reagent (Roche Applied Sciences). Cells were incubated for 40–48 h and then cross-linked with formaldehyde, harvested, and ChIP was performed. For these studies, only  $5 \times 10^6$  cells were used per immunoprecipitation reaction since the plasmid is present at a high copy number. The remainder of the procedure followed standard protocols for ChIP analysis, as has been described in Upstate protocol. The resulting DNA was analyzed by PCR reactions using the following HIV-LTR primers: (sense)(–120) 5' aactggtaccatcgagcttgc 3' and (anti-sense) (+66) 5' ttgaggatccagcagtgggttc 3'. Antibody used in the ChIP procedure is p65 or C/EBP $\beta$  (from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as well as rabbit anti-mouse IgG.

The specificity of the bands obtained by PCR was analyzed using Southern blot hybridization. Briefly, PCR products were isolated from agarose gels and transferred to a nylon membrane (Amersham, Piscataway, NJ) using a Turbo-blotter system (Schleicher & Schuell, Keene, NH) according to the manufacturer's instructions. The DNA probes were then labeled using a random primer labeling reaction with Klenow enzyme and  $\alpha^{32}$ P dCTP as previously described [Sweet et al., 2003]. The primers used

for PCR are as follow: (–80) GGGAGGTACCA-GGGAGGCGTGG and (+3) CAGAGGATCC-CAGTACA GGCAA from LTR region.


## RESULTS AND DISCUSSION

Earlier observations on cell free interaction of p65 and C/EBP $\beta$  with HIV-1 LTR DNA prompted us to examine whether this event can also occur in living cells where either protein is overexpressed. Further, to assess the possible cooperative or antagonistic effect of p65 and C/EBP $\beta$  on each other's DNA binding activity, we transfected HL3T1, a cell line that contains integrated DNA segment of the HIV-1 LTR fused to the *CAT* gene (Fig. 1A) with p65 and/or C/EBP $\beta$  expression plasmids. Forty-eight hours post-transfection, the cells were harvested and processed for chromatin immunoprecipitation (ChIP) assay. To examine the basal binding of p65 and/or C/EBP $\beta$ , untransfected cells were also used in the study. ChIP assay was performed using antibodies directed against p65 protein as well as rabbit anti-mouse serum as a negative control. As shown in Figure 1B, endogenous as well as ectopically expressed p65 bind to HIV-LTR DNA (lanes 3 and 6), and as expected, an increase in the level

of p65–DNA complex was observed when p65 was ectopically expressed (compare lanes 3 and 6). The p65–DNA interaction was noticeably elevated in cells co-expressing p65 and C/EBP $\beta$  (lane 12) but not in cells with only C/EBP $\beta$  overexpression (lane 9). No DNA–protein complexes were observed when the control serum was used (lanes 2, 5, 8, and 11).


In a reciprocal study, we utilized antibody directed against C/EBP $\beta$  in ChIP assay. Again, rabbit anti-mouse serum was used as a negative control. As shown in Figure 1C, endogenous and over-expressed C/EBP $\beta$  proteins bind to HIV-LTR DNA with the same intensity, suggesting that C/EBP $\beta$  may occupy the promoter of the LTR (lanes 3 and 6). A slight decrease of C/EBP $\beta$ –DNA interaction was observed when the cells were co-transfected with C/EBP $\beta$  and p65 (compare lane 12 to lanes 3 and 6) but not with p65 alone (compare lanes 9 and 12). No interaction was observed when the non-specific control serum was used in the precipitation steps (lanes 2, 5, 8, and 11).

Next we sought to assess the effect of Tat on the binding of p65 or C/EBP $\beta$  to DNA. To that end, HL3T1 cells were transfected with Tat, p65, and C/EBP $\beta$  expression plasmids using various combinations. As shown in Figure 2A,



**Fig. 1.** Interaction of p65 and C/EBP $\beta$  with the LTR. **A:** Schematic representation of the HIV-1 LTR (–120/+80). The potential binding sites of several DNA-binding transcription factors are also indicated. **B** and **C:** HL3T1 cells were transfected with 1.0  $\mu$ g of p65 (**Panel B**, lanes 4–6 and 10–12, and **Panel C**, lanes 7–12) or C/EBP $\beta$  (**Panel C**, lanes 4–6 and 10–12, and **Panel B**, lanes 7–12) expression plasmid as indicated. Interaction of

p65 or C/EBP $\beta$  with HIV-LTR was demonstrated by ChIP assay. The primers used in these experiments are described in Materials and Methods. Anti-p65 (**Panel B**, lanes 3, 6, 9, and 12), anti-C/EBP $\beta$  (**Panel C**, lanes 3, 6, 9, and 12), pre-immune serum (**Panel B** and **C**, lanes 2, 5, 8, and 11), and no antibody (lanes 1, 4, 7, and 10) were used in these experiments.



**Fig. 2.** Effect of Tat on in vivo association of p65 and C/EBPβ with LTR. **A** and **B**: HL3T1 cells were transfected with HIV-1 Tat, p65, or C/EBPβ expression plasmids as indicated. Interaction of p65 or C/EBPβ with HIV-LTR in the presence of Tat was demonstrated by ChIP assay. Anti-p65 or anti-C/EBPβ antibodies, pre-immune serum, and no antibody were used in these experiments. **C** and **D**: Histogram representing the values of

each band obtained from ChIP using densitometry. The values are based on the arbitrary units of 1–200 and the baseline derived from control without Tat was set at 100. **E** and **F**: Western blot analysis using anti-p65 and anti-C/EBPβ antibodies demonstrated the specificity of the antibodies. Arrows indicate the positions of p65 and the various C/EBPβ isoforms.


endogenous and ectopic p65 were able to associate with LTR DNA (lanes 3 and 6) in the presence of Tat with a similar efficiency as seen in the absence of Tat (compare Fig. 1B, lanes 3 and 6 to Fig. 2A, lanes 3 and 6). Co-expression of Tat and C/EBPβ slightly decreased p65–DNA interaction (compare lanes 3 and 9) (also compare Fig. 1B, lanes 3 and 9). Interestingly,

in the presence of Tat, cells with ectopic expression of C/EBPβ and p65 showed a significant decrease in the binding of p65 to LTR (compare lanes 12 Fig. 2A) (also compare lanes 12 in Fig. 1B). In this regard, we should add that we previously demonstrated the ability of Tat to associate with C/EBPβ [Abraham et al., 2005]. Therefore, the observed decrease could be

explained by the formation of a Tat–C/EBP $\beta$  complex, which leads to an inhibition of p65–DNA complex formation and suppression of p65 transcriptional activity. No interaction was observed when the, non-specific control, serum was used (lanes 2, 5, 8, and 11).

When ChIP assay was performed using anti-C/EBP $\beta$  antibody, C/EBP $\beta$ –DNA association showed no change in cells expressing Tat or Tat plus p65 (Fig. 2B, compare lanes 3 and 9). Surprisingly, C/EBP $\beta$ –DNA interaction showed an elevation in cells expressing Tat and C/EBP $\beta$  (compare lanes 3 and 6). Differences in the levels of interaction of p65 or C/EBP $\beta$  to the DNA were further evaluated by densitometric analysis using Scion image software (Scion Image Corp) (Fig. 2, panels C and D). The values represent the percentage of variation in the intensity of p65–DNA or C/EBP $\beta$ –DNA complexes. Similar results were obtained with Jurkat cells, which led us to conclude that the events may also occur in T-cells (data not shown). It should be noted that the specificity of the antibodies was examined using Western blot analysis using anti-p65 and anti-C/EBP $\beta$  as shown in Figure 2 (panels E and F).

Next, we sought to determine the functional interplay of p65 and C/EBP $\beta$  upon LTR transcription in Tat-producing HL3T1 cells. As anticipated, Tat-enhanced HIV-1 promoter activity in HL3T1 cells (Fig. 3, lane 2). Express-




**Fig. 3.** Transcription regulation of HIV-1 promoter by p65 and C/EBP $\beta$  in the presence of Tat. HL3T1 cells were transfected with 1.0  $\mu$ g of Tat, p65, or C/EBP $\beta$  expression plasmids, as indicated. Total amount of transfected DNA was kept constant by the addition of empty control vector. The data represent the mean value of at least three separate transfection experiments. Cell extracts were prepared 48 h after transfection and CAT activity was determined as described [Coyle-Rink et al., 2002].

sion of p65 and C/EBP $\beta$  enhanced, albeit to various extents, Tat activation of the LTR, respectively (compare lane 2 to lanes 4 and 6). Interestingly, C/EBP $\beta$  decreased the level of p65 and Tat cooperativity as evidenced by the decrease in the level of LTR transcription (compare lane 4 to lane 8). Lanes 3, 5, and 7 represent the basal levels of p65 and/or C/EBP $\beta$  on HIV-1 LTR.

To further confirm the significance of p65–DNA association and p65–C/EBP $\beta$  functional interplay, we knocked down p65 expression using small interference RNA directed against p65 (siRNA-p65). As shown in Figure 4A, p65 was silenced in extracts prepared from siRNA-transfected cells (compare lanes 1 and 3). Note that control non-targeting siRNA was used as a negative control (lane 2). Results from ChIP assay showed that a decrease in the level of p65 can negatively impact on p65 as well as C/EBP $\beta$  association with LTR, and that this event can occur in the absence and presence of Tat.

In this report, we demonstrate the functional association of members of two important transcription factor families that include p65 subunit of NF- $\kappa$ B and C/EBP $\beta$  of C/EBP with each other and their impact on HIV-1 LTR transcription. The functional association is characterized by (i) the inhibition of p65-induced expression of HIV-1 LTR by C/EBP $\beta$  and (ii) the enhancement of p65 association with the DNA in the presence of C/EBP $\beta$ . This functional interplay is more evident in the presence of HIV-1 Tat.

The functional interaction between members of the two families is not without precedent. Earlier studies have shown existence of a



**Fig. 4.** Effect of p65 on interaction of C/EBP $\beta$  with the LTR in the absence and presence of Tat. **A:** HL3T1 cells were transfected with siRNA-p65 (5'-GCCCUAUCUUUUACGUCAdTdT; Dharmacon Research, Inc., Lafayette, CO). Approximately, 50  $\mu$ g of extract were utilized in Western blot assay utilizing anti-p65 or anti-Grb2 antibodies, respectively. Cells transfected only with pcDNA3 were utilized as negative controls. The arrows depict the positions of the different proteins. **B:** ChIP assay was performed to evaluate p65 and C/EBP $\beta$  association with the DNA after 48 h of siRNA-p65 transfection in the presence or absence of Tat.

physical interaction between the various members of NF- $\kappa$ B, (i.e., p50, p65, and c-Rel) through the Rel homology domain with the bZIP region of C/EBP ( $\alpha$ ,  $\beta$ , and  $\delta$ ) [Stein et al., 1993]. The nature of the molecular complex (i.e., domains of interaction, heterodimer formation) formed between p65 and C/EBP $\beta$  remains unknown. Previous studies have shown that a mutation in the putative p65 leucine zipper domain does not block the functional or physical interaction between p65 and C/EBP $\beta$ . On the contrary, an alternatively spliced form of p65 fails to interact with C/EBP $\beta$  subunits [Stein et al., 1993]. These observations suggest that the same motif that is necessary for dimerization of NF- $\kappa$ B may also be involved in its cross-interaction with C/EBP $\beta$ . Further, earlier reports suggest that a single C/EBP binding site may be sufficient to serve as a target for its cooperativity with NF- $\kappa$ B subunits [Cha-Molstad et al., 2000]. Based on this information, one may envision a model in which a dimer of a C/EBP family member interacts with the DNA motif and associates through its bZIP region with the Rel homology region of NF- $\kappa$ B family member. In this regard, and based on our results, the functional interplay between p65 and C/EBP $\beta$  is more obvious as shown in Figures 1 and 4, where we show that C/EBP $\beta$  interacts more efficiently with the DNA in the presence of p65 than in its absence. These results could be explained by the dependency of C/EBP $\beta$  in the presence of p65 in order to bind and activate the HIV-LTR. Further, these results may also point to a potential role for p65 in the stabilization of C/EBP $\beta$ , which may explain the observed data.

Functional interaction of NF- $\kappa$ B and C/EBP may also explain IL-1 and IL-6 cooperativity. IL-1 is known to induce NF- $\kappa$ B [Miyazawa et al., 1998], whereas IL-6 activates C/EBP $\beta$  [Xia et al., 1997]. The physical and functional interactions observed between p65 and C/EBP $\beta$  may explain the functional synergy observed between IL-1 and IL-6 in several physiological responses [Murakami et al., 2001]. Further, functional interactions between C/EBP $\beta$  and p65 subunits could have profound influences on cellular growth control. It has been demonstrated that C/EBP $\alpha$  is growth inhibitory and likely functions in the terminal differentiation of certain cells [Xia et al., 1997]. The expression of C/EBP isoforms could alter the ability of NF- $\kappa$ B subunits to control cellular proliferation.

Here we utilized ChIP assays to illustrate in vivo association of NF- $\kappa$ B and C/EBP factors to their respective DNA-binding sites on HIV-1 LTR. In co-transfection experiments, we demonstrated that p65 and C/EBP $\beta$  alone or co-expressed along with Tat modulate the HIV-1 promoter activity. These observations correlate with the previous reports on cooperativity of C/EBP $\beta$  and NF- $\kappa$ B upon transcription of Fas promoter [Darville and Eizirik, 2001]. In their study, the authors demonstrated that addition of p65 inhibits transactivation of Fas promoter by C/EBP $\beta$ . Recent studies also revealed cross-talk between C/EBP and NF- $\kappa$ B pathways in TNF- $\alpha$  signaling [Papin et al., 2003]. Cross-family interactions of specific transcription factors within a particular family were also demonstrated between the GR and the AP-1 family of proteins (i.e., Fos and Jun) [Ogata et al., 2003], or between the leucine zipper protein Jun and the helix-loop-helix protein MyoD [Finkel et al., 1993].

In summary, we conclude that the regulation of gene expression is not mediated solely by the presence or absence of a particular set of transcription factors. The function of any particular transcription factor can be inhibited by the presence of another factor or a specific inhibitor that blocks the ability of that particular transcription factor to bind to DNA. In addition, our data demonstrate that the important transcription factor families C/EBP and NF- $\kappa$ B functionally interact. This observation, along with those made previously, highlights a unique mechanism by which the levels of one transcription factor can strongly modulate the functional activity of another.

#### ACKNOWLEDGMENTS

We thank past and present members of the Center for Neurovirology and Department of Neuroscience for sharing ideas and reagents. This work was supported by Grants awarded by NIH (NINDS) to K.K. and S.A.

#### REFERENCES

- Abraham S, Sweet T, Sawaya BE, Rappaport J, Khalili K, Amini S. 2005. Cooperative interaction of C/EBP $\beta$  and Tat modulates MCP-1 gene transcription in astrocytes. *J Neuroimmunol* 160:219–227.
- Amini S, Clavo A, Nadruga Y, Giordano A, Khalili K, Sawaya BE. 2002. Interplay between cdk9 and NF- $\kappa$ B factors determines the level of HIV-1 gene transcription in astrocytic cells. *Oncogene* 21:5797–5803.

- Barber SA, Herbst DS, Bullock BT, Gama L, Clements JE. 2004. Innate immune responses and control of acute simian immunodeficiency virus replication in central nervous system. *J Neurovirol* 10:15–20.
- Cassel TN, Nord M. 2003. C/EBP transcription factors in the lung epithelium. *Am J Physiol Lung Cell Mol Physiol* 285:L773–L781.
- Cha-Molstad H, Agrawal A, Zhang D, Samols D, Kushner I. 2000. The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. *J Immunol* 165:4592–4597.
- Chun RF, Semmes OJ, Neuveut C, Jeang KT. 1998. Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. *J Virol* 72:2615–2629.
- Coyle-Rink J, Sweet T, Abraham S, Sawaya BE, Batuman O, Khalili K, Amini S. 2002. Interaction between TGFbeta signaling proteins and C/EBP controls basal and Tat-mediated transcription of HIV-1 LTR in astrocytes. *Virology* 299:240–247.
- Darville MI, Eizirik DL. 2001. Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-kappaB and C/EBP. *Diabetes* 50:1741–1748.
- Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M. 1996. Activation of transcription factor NF-kappa B by Tat protein of human immunodeficiency virus type-1. *J Virol* 70:4427–4437.
- Finkel T, Duc J, Fearon ER, Dang CV, Tomaselli GF. 1993. Detection and modulation in vivo of helix-loop-helix protein-protein interactions. *J Biol Chem* 268:5–8.
- Ghosh S, Karin M. 2002. Missing pieces in NF-kappa B puzzle. *Cell* 109:S81–S96.
- Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: The control of NF-kB activity. *Ann Rev Immunol* 18:621–663.
- Mischitelli M, Fioriti D, Videtta M, Degener AM, Antinori A, Cinque P, Giordano A, Pietropaolo V. 2005. Investigation on the role of cell transcriptional factor Sp1 and HIV-1 TAT protein in PML onset or development. *J Cell Physiol* 204:913–918.
- Miyazawa K, Mori A, Yamamoto K, Okudaira H. 1998. Transcriptional roles of CCAAT/enhancer binding protein-beta, nuclear factor-kappaB, and C-promoter binding factor 1 in interleukin (IL)-1beta-induced IL-6 synthesis by human rheumatoid fibroblast-like synovocytes. *J Biol Chem* 273:7620–7627.
- Murakami S, Hashikawa T, Saho T, Takedachi M, Nozaki T, Shimabukuro Y, Okada H. 2001. Adenosine regulates the IL-1 beta-induced cellular functions of human gingival fibroblasts. *Int Immunol* 13:1533–1540.
- Muthumani K, Choo AY, Hwang DS, Chattergoon MA, Dayes NN, Zhang D, Lee MD, Duvvuri U, Weiner DB. 2003. Mechanism of HIV-1 viral protein R-induced apoptosis. *Biochem Biophys Res Commun* 304:583–592.
- Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. *Nature* 326:711–713.
- Ogata K, Sato K, Tahirov TH. 2003. Eukaryotic transcriptional regulatory complexes: Cooperativity from near and afar. *Curr Opin Struct Biol* 13:40–48.
- Pande V, Ramos MJ. 2003. Nuclear factor kappa B: A potential target for anti-HIV chemotherapy. *Curr Med Chem* 10:1603–1615.
- Papin S, Cazeneuve C, Duquesnoy P, Jeru I, Sahali D, Amselem S. 2003. The tumor necrosis factor alpha-dependent activation of the human mediterranean fever (MEFV) promoter is mediated by a synergistic interaction between C/EBP beta and NF kappaB p65. *J Biol Chem* 278:48839–48847.
- Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. 2000. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. *Nuc Acids Res* 28:663–668.
- Phelps CB, Sengchanthalangsy LL, Huxford T, Ghosh G. 2000. Mechanism of I kappa B alpha binding to NF kappa B dimer. *J Biol Chem* 275:29840–29846.
- Sawaya B, Thatikunta P, Denisova L, Brady J, Khalili K, Amini S. 1998. Regulation of TNF alpha and TGFbeta-1 gene transcription by HIV-1 Tat in CNS cells. *J Neuroimmunol* 87:33–42.
- Schwartz C, Catez P, Rohr O, Lecestre D, Aunis D, Schaeffer E. 2000. Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells. *J Virol* 74:65–73.
- Stein B, Cogswell PC, Baldwin AS. 1993. Functional and physical associations between NF-kappa B and C/EBP family members: A Rel domain-bZIP interaction. *Mol Cell Biol* 13:3964–3974.
- Surabhi RM, Gaynor RB. 2002. RNA Interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. *J Virol* 76:12963–12973.
- Sweet T, Khalili K, Sawaya BE, Amini S. 2003. Identification of a novel protein from glial cells based on its ability to interact with NF-kappa B subunits. *J Cell Biochem* 90:884–891.
- Tesmer VM, Rajadhyaksha A, Babin J, Bina M. 1993. NF-IL6-mediated transcriptional activation of the long terminal repeats of the human immunodeficiency virus type 1. *Proc Natl Acad Sci* 90:7298–7302.
- Trubiani O, De Fazio P, Pieri C, Mazzanti L, Di Primio R. 2000. Nuclear matrix provides linkage sites for translocated NF-kappa B: Morphological evidence. *Histochem Cell Biol* 113:369–377.
- West MJ, Lowe AD, Karn J. 2001. Activation of human immunodeficiency virus transcription in T cells revisited: NFkB p65 stimulates transcriptional elongation. *J Virol* 75:8524–8537.
- Xia C, Cheshire JK, Patel H, Woo P. 1997. Cross-talk between transcription factors NF-kappa B and C/EBP in the transcriptional regulation of genes. *Intelligence J Biochem Cell Biol* 29:1525–1539.